Beijing Leadman Biochemistry Co Ltd

Leadman released its 2026 interim report. Total operating revenue was 152 million yuan, down 5.31% year-on-year. Net loss attributable to the parent company was 7.113 million yuan, a decrease of 2.8679 million yuan compared with the same period last year, with the loss widening year-on-year. Net cash inflow from operating activities was 9.2498 million yuan, up 947.07% year-on-year. The company's asset-liability ratio was 5.24%, gross margin was 43.44%, return on equity was negative 0.44%, and diluted earnings per share was negative 0.01 yuan. The number of shareholders was 25,000, and the top ten shareholders held 50.87% of the total share capital.

Leadman published its 2026 interim report. First-half operating revenue was 152 million yuan, down 5.3 percent year on year, while net profit attributable to the parent swung from a loss of 4.25 million yuan a year earlier to a loss of 7.11 million yuan. Second-quarter operating revenue was 81.5 million yuan, down 0.1 percent year on year, and the net loss attributable to the parent was 3.14 million yuan, wider than the 2.99 million yuan loss in the same period last year. As of the end of the second quarter, total assets were 1.756 billion yuan, down 1.1 percent from the end of the previous year, and net assets attributable to the parent were 1.632 billion yuan, down 0.4 percent. In vitro diagnostic reagents remained the main revenue source, generating 111 million yuan, up 1.69 percent year on year and accounting for 72.85 percent of operating revenue. Diagnostic instruments brought in 17.23 million yuan, down 24.23 percent, representing 11.34 percent of revenue. Biochemical raw materials contributed 6.81 million yuan, down 11.32 percent, or 4.48 percent of revenue. Other businesses generated 17.22 million yuan, down 18.75 percent, or 11.33 percent of revenue. The company's operating model is mainly distribution-based, with distribution revenue of 123 million yuan accounting for 90.98 percent of main business revenue, while direct sales revenue was 12.16 million yuan, or 9.02 percent. The company flagged risks including changes in industry policy and intensifying market competition, and said it has taken measures to address them.